Erythrokeratoderma are diverse group of genodermatosis affecting keratinization under which, Erythrokeratodermia Variabilis ( EKV) was rst described in 1925 by Mendes da Costa. Our patient is a 48 year old male presenting clinically with EKV Mendes Da Costa, hyperkeratotic subtype with the histopathology supportive of the diagnosis. We are reporting for its rarity and due to its late onset in our patient and also for the sporadic nature of this particular case of EKV.
INTRODUCTION
Erythrokeratoderma are diverse group of rare genodermatosis affecting keratinization characterized by well demarcated [1] erythematous, hyperkeratotic plaques either migratory or stationary. A recent proposal to name it as Erythrokeratodermia variabilis et progressiva (EKVP) as there is overlapping of clinical features along with underlying same genetic mutations of Erythrokeratodermia variabilis (EKV) with Progressive symmetric erythrokeratoderma [2] (PSEK). 
Case Report

DISCUSSION
Classical Erythrokeratodermia Variabilis (EKV) /Mendes da Costa syndrome rst described in 1925 by Mendes da Costa is usually inherited as autosomal dominant disorder with few cases of autosomal recessive pattern inheritance. The very few sporadic cases reported could be due to Denovo or new gene mutations where there is no [3] history of family members being affected. EKV has been reported worldwide. Both genders are affected equally and there is no racial predilection. Onset is usually at birth or early infancy. But it may be [4, 5] seen in childhood or manifest even later in adults.
Our patient had no positive family history and onset was in adulthood. rd In about 2/3 of EKV patients, mutations in GJB3 encoding connexin [1, 3] 31 or GJB4 encoding connexin 30.3 have been found.
In the skin, Cx31 and Cx30.3 are expressed in stratum granulosum. Connexins form gap junctions which are aqueous intercellular channels which are rd important for normal epidermal differentiation. Rest 1/3 of cases have no known mutations in the connexin genes suggesting genetic [3.6] heterogeneity.
Clinical features of EKV is characterized by two distinct skin lesions a) relatively xed well demarcated hyperkeratotic plaques often bizzarely shaped showing predilection for extensor surfaces of extremities, lateral trunk & buttocks. b) Transient erythematous, polycyclic or comma shaped patches occurring at any [7, 8] site which may change its distribution and last days or weeks. One [6] feature may predominate or sometimes can be absent or missing. This was noted in our case which is of the EKV hyperkeratotic type. Atypical variants are en cocardes type, reticulate type & erythema [8] gyratum repens-like type. Palms and soles may show diffuse hyperkeratosis. Palmoplantar keratoderma and lesions involving face [9] are seen more in PSEK than in EKV. Our patient had neither features.
Differential diagnoses are Progressive symmetric erythrokeratoderma (PSEK), Keratitis-ichthyosis-deafness (KID) syndrome, Netherton Syndrome, Schnyder syndrome, Greither syndrome, Giroux-barbeau syndrome. Others are plaques of psoriasis, urticaria in early stages. Atypical variants have to be differentiated from Erythema annulare [8] centrifugam, erythema multiforme, subacute lupus erythematosus.
Besides histopathological examination, if available genetic studies can be done to detect connexin genes mutation. EKV has a chronic course with remissions & exacerbations. Treatment is mainly directed at diminishing the hyperkeratosis to minimize discomfort. Current line of treatments are topical keratolytics, topical retinoids, tazorotene, topical corticosteroids and systemic retinoids acitretin, etretinate and isotretinion. Our patient was started on oral Acitretin 25mg, emollients & keratolytics and is under follow up. Some studies have tried Psoralen [10] plus ultraviolet A (PUVA).
Avoidance of mechanical irritation, exposure to extreme temperature changes are advised as general measures. Recent interest has been using drugs affecting connexions hemichannels including antimalarials-meoquine, aminoglycosidegentamycin and streptomycin, glycyrrhetinic acid-carbenoxolone disodium and benzopyran-tonabersat in the management of connexin [6] implicated conditions.
Further studies need to be done for the evaluation of their efcacy in EKV.
CONCLUSION
As the name suggests, Erythrokeratodermia variabilis can have variable clinical presentations as noted in our patient. This case has been reported for its rarity and due to its late onset in our patient and also for the sporadic nature of this particular case of EKV.
